Drug intelligence / Profile preview

88BV59H21-2

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

88BV59H21-2 is a technetium-99m (99mTc) labeled F(ab')₂ fragment of the monoclonal antibody 88BV59. This radioimmunoconjugate is designed for use in cancer imaging. The F(ab')₂ fragment targets specific antigens expressed on tumor cells, and the technetium label enables detection via planar and SPECT imaging modalities. The preparation involves mild reductive labeling with technetium to preserve antibody integrity and binding specificity. Clinical studies have demonstrated localization of the radiolabeled antibody in cancer lesions, supporting its utility as a diagnostic agent for tumor detection[5].

Beyond the preview

Go deeper on 88BV59H21-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 88BV59H21-2.

Explore the full profile